Orange County Business Journal

Valeant Sets Bid at $47B

Jane Yu Tuesday, April 22, 2014

Valeant Pharmaceuticals Inc., an unsolicited suitor of Irvine-based drug maker Allergan Inc., has set its bid for the acquisition at $47 billion.

Canada-based Valeant, which has partnered with Bill Ackman’s Pershing Square Capital Management LP in the proposal, said today it is offering $48.30 in cash and 0.83 shares of its common stock per Allergan share. It said Allergan shareholders would own 43% of the combined entity’s stock.

Allergan shares are up about 16% during morning trading to a market value of about $48.9 billion. Valeant shares also are up, about 6%, to a market value of about $44 billion.

Valeant said it’s expecting $2.7 billion in operating cost synergies as a result of the combination. It estimated that full-year revenue, given certain assumptions, could range between $14.8 billion and $15.5 billion.

Allergan’s board of directors said it will “carefully review and consider the proposal and pursue the course of action that it believes is in the best interests of the company’s stockholders.”

Facebook Twitter Linked-In